---
schema_version: "secwatch.filing_event.v1"
accession: "0001816590-25-000094"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:46:53.772130+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Compass Pathways appoints Justin Gover to board; Dr. Linda McGoldrick to retire Oct 31

## Summary
- Justin Gover appointed as Class III director effective July 29, 2025; joins audit/risk and scientific committees.
- Gover receives initial option for 52,000 ordinary shares vesting over 3 years; annual retainer of $40,000 plus committee fees.
- Linda McGoldrick to retire from board effective October 31, 2025; no disagreement with company.
- Gover was founding CEO of GW Pharmaceuticals (sold to Jazz for $7B) and led Epidiolex development/commercialization.
- Currently also serves on Xenon Pharmaceuticals (XENE) board; brings 25+ years biopharma experience.

## SEC filing metadata
- accession: 0001816590-25-000094
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000181659025000094/0001816590-25-000094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000181659025000094/cmps-20250728.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001816590-25-000094
- JSON: https://secwatch.observer/filing/0001816590-25-000094.json
- Plain text: https://secwatch.observer/filing/0001816590-25-000094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.